Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
149.4 USD | -3.20% | +0.99% | -21.92% |
Kurzporträt
Mitarbeiterzahl: 2 100
Umsatz nach Geschäftsbereich
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Ribonucleic Acid Interference Therapeutics
100,0
%
| 1 037 | 100,0 % | 1 828 | 100,0 % | +76.23% |
Umsatz je Region
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
69,8
%
| 616 | 59,4 % | 1 276 | 69,8 % | +107.21% |
Europe
21,8
%
| 315 | 30,4 % | 399 | 21,8 % | +26.83% |
Rest of the World
8,4
%
| 107 | 10,3 % | 153 | 8,4 % | +43.31% |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Chief Executive Officer | 61 | 19.09.16 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 56 | 13.08.19 |
Piyush Sharma
CMP | Compliance Officer | - | 21.09.22 |
Chief Tech/Sci/R&D Officer | - | 01.08.17 | |
Kevin Fitzgerald
CTO | Chief Tech/Sci/R&D Officer | 56 | 01.01.05 |
James Bilotta
CTO | Chief Tech/Sci/R&D Officer | - | 01.10.15 |
Pushkal Garg
CTO | Chief Tech/Sci/R&D Officer | 56 | 29.10.14 |
Joshua Brodsky
IRO | Public Communications Contact | - | 01.02.21 |
Investor Relations Contact | 43 | 01.09.15 | |
Eric Green
PRN | Corporate Officer/Principal | - | - |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 18.12.15 |
Charles Sigal
BRD | Director/Board Member | 72 | 22.08.22 |
Margaret Hamburg
BRD | Director/Board Member | 68 | 10.01.19 |
Amy Schulman
CHM | Chairman | 63 | 01.07.14 |
Phillip Sharp
FOU | Founder | 79 | 14.06.02 |
Peter Kellogg
BRD | Director/Board Member | 68 | 07.03.23 |
Michael Bonney
BRD | Director/Board Member | 65 | 17.12.14 |
Dennis Ausiello
BRD | Director/Board Member | 78 | 23.04.12 |
Colleen Reitan
BRD | Director/Board Member | 64 | 01.06.18 |
Chief Executive Officer | 61 | 19.09.16 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 125 945 793 | 125 446 997 ( 99,60 %) | 0 | 99,60 % |
Unternehmenskontakt
Alnylam Pharmaceuticals, Inc.
675 West Kendall Street Henri A. Termeer Square
02142, Cambridge
+617 551 8200
http://www.alnylam.comSektor
Umsatz je Region
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
-21.92% | 19.44 Mrd. | |
+9.30% | 45.97 Mrd. | |
+52.73% | 43.93 Mrd. | |
+7.15% | 42.34 Mrd. | |
-8.78% | 28.27 Mrd. | |
+18.68% | 27.18 Mrd. | |
+14.62% | 13.83 Mrd. | |
+31.85% | 12.4 Mrd. | |
+4.47% | 11.45 Mrd. | |
-8.77% | 10.91 Mrd. |
- Börse
- Aktien
- Aktie Alnylam Pharmaceuticals, Inc. - Nasdaq
- Unternehmen Alnylam Pharmaceuticals, Inc.